Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial -

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial
Information type: Randomised controlled trials
Source: Journal of the American Medical Association
Specialities: Infection and infectious diseases | Renal and urologic disorders
Summary
RCT (n=550) found difference in composite outcome of complete resolution/improvement of symptoms plus microbial eradication met noninferiority margin of 15% when comparing meropenem-vaborbactam with piperacillin-tazobactam (98.4 vs 94.0%) for the treatment of complicated UTI.
UKMi comment
Meropenem-vaborbactam was approved in US for treatment of adults with complicated urinary tract infections last year. It was filed for approval in EU in July 2017.
Related links: